Stocks · News reference
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-28 AccNo: 0001104659-26-111408 Size: 274 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Filed: 2026-09-17 AccNo: 0001104659-26-108405 Size: 1 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Chief Commercial OfficerAccendra Health also today named Scott Lloyd to the role of Chief Commercial Officer, effective October 5, 2026. The Company created the position to bring commercial strategy, sales, and provider
Gardner-Smith to Succeed Ed Pesicka Following Previously Announced RetirementCompany Announces Scott Lloyd as Chief Commercial OfficerAccendra Health, Inc. (NYSE:ACH) (the "Company") today named Kenneth